日韩精品久久无码中文字幕,色欲av无码一区二区三区,少妇无码一区二区三区,精品久久久久国产免费

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73191SLC34A2-ROS1/BaF3

SLC34A2-ROS1/BaF3
名稱 SLC34A2-ROS1/BaF3
型號 CBP73191
報價
特點 SLC34A2-ROS1/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO;
  • 詳細內(nèi)容
CBP73191
I. Introduction

Cell Line Name:

SLC34A2-ROS1/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).


III. Representative Data

1. WB of SLC34A2-ROS1 expression

CBP73191 WB.png



2.Sanger Sequencing of SLC34A2-ROS1 Fusion

CBP73191 sanger.png

2. Anti-proliferation assay

CBP73191 fig.png

Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.


如果你對CBP73191SLC34A2-ROS1/BaF3感興趣,想了解更詳細的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
亚洲成av人片天堂网| 久久久久久无码大片a片| 欧美日韩在线视频| 日韩精品视频| WWW国产精品内射老熟女| 国产精品视频一区二区噜噜| 婷婷色婷婷开心五月四房播播| 国产裸体舞一区二区三区| 久久国产精品无码一区二区三区 | 中文字幕乱偷无码av先锋| 在野外自慰和陌生人做了| 勃起大粗又硬湿又滑深又长| 亚洲av无码一区二区乱子仑 | 18禁免费无码无遮挡不卡网站| 人妻~夫の上司犯感との| 日本簧片在线观看| 青青草97国产精品免费观看 | 少妇高潮惨叫久久久久久| 又粗又大又硬毛片免费看| 色噜噜狠狠一区二区三区果冻| 国产做a爱免费视频在线观看| 美女100%裸体| 亚洲男人第一av网站| 在线观看免费视频| 亚洲人成色在线观看| 国产边添边摸边做边爱| 国产精品美女久久久久久久 | 人妻 校园 激情 另类| 男女交性视频播放| 国产爆乳无码一区二区麻豆| 亚洲av综合色区无码一区爱av| 美妙人妇系列1~100| 亚洲成av人综合在线观看 | 国产精品欧美一区二区三区| 人妻丝袜无码国产一区| 撑开毛都没长齐的小缝| 色噜噜狠狠一区二区三区果冻| 精品香蕉一区二区三区| 国产成人精品A视频一区| 国产精品久久毛片a片| 亚洲精品国偷拍自产在线观看蜜臀 |